183 related articles for article (PubMed ID: 32916569)
1. Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms.
Rubino M; Scoazec JY; Pisa E; Faron M; Spaggiari L; Hadoux J; Spada F; Planchard D; Cella CA; Leboulleux S; De Marinis F; Ducreux M; Lamartina L; Baudin E; Fazio N
Lung Cancer; 2020 Oct; 148():149-158. PubMed ID: 32916569
[TBL] [Abstract][Full Text] [Related]
2. Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices.
Rekhtman N; Desmeules P; Litvak AM; Pietanza MC; Santos-Zabala ML; Ni A; Montecalvo J; Chang JC; Beras A; Preeshagul IR; Sabari JK; Rudin CM; Ladanyi M; Klimstra DS; Travis WD; Lai WC
Mod Pathol; 2019 Jul; 32(8):1106-1122. PubMed ID: 30923345
[TBL] [Abstract][Full Text] [Related]
3. Molecular markers help characterize neuroendocrine lung tumors.
Rusch VW; Klimstra DS; Venkatraman ES
Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011
[TBL] [Abstract][Full Text] [Related]
4. Automated quantification of Ki-67 proliferative index of excised neuroendocrine tumors of the lung.
Liu SZ; Staats PN; Goicochea L; Alexiev BA; Shah N; Dixon R; Burke AP
Diagn Pathol; 2014 Oct; 9():174. PubMed ID: 25318848
[TBL] [Abstract][Full Text] [Related]
5. The Role of Histologic Grading and Ki-67 Index in Predicting Outcomes in Pulmonary Carcinoid Tumors.
Dermawan JKT; Farver CF
Am J Surg Pathol; 2020 Feb; 44(2):224-231. PubMed ID: 31490236
[TBL] [Abstract][Full Text] [Related]
6. The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: current best evidence.
Marchevsky AM; Hendifar A; Walts AE
Mod Pathol; 2018 Oct; 31(10):1523-1531. PubMed ID: 29802361
[TBL] [Abstract][Full Text] [Related]
7. Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids.
Naraev BG; Ramirez RA; Kendi AT; Halfdanarson TR
Clin Lung Cancer; 2019 May; 20(3):e376-e392. PubMed ID: 30910575
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine tumor G3 of bronchopulmonary origin and its classification.
Kasajima A; Klöppel G
Pathol Int; 2022 Oct; 72(10):488-495. PubMed ID: 35983917
[TBL] [Abstract][Full Text] [Related]
9. The Ki-67 antigen in the new 2021 World Health Organization classification of lung neuroendocrine neoplasms.
Pelosi G; Travis WD
Pathologica; 2021 Oct; 113(5):377-387. PubMed ID: 34837096
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours.
Clay V; Papaxoinis G; Sanderson B; Valle JW; Howell M; Lamarca A; Krysiak P; Bishop P; Nonaka D; Mansoor W
Clin Transl Oncol; 2017 May; 19(5):579-586. PubMed ID: 27848218
[TBL] [Abstract][Full Text] [Related]
11. Natural History of Localized and Locally Advanced Atypical Lung Carcinoids after Complete Resection: A Joined French-Italian Retrospective Multicenter Study.
Marciello F; Mercier O; Ferolla P; Scoazec JY; Filosso PL; Chapelier A; Guggino G; Monaco R; Grimaldi F; Pizzolitto S; Guigay J; de Latour BR; Giuffrida D; Longchampt E; de Montpreville VT; Fadel E; Colao A; Planchard D; Papotti M; Faggiano A; Baudin E
Neuroendocrinology; 2018; 106(3):264-273. PubMed ID: 28813709
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.
Neubauer E; Wirtz RM; Kaemmerer D; Athelogou M; Schmidt L; Sänger J; Lupp A
Oncotarget; 2016 Jul; 7(27):41959-41973. PubMed ID: 27259241
[TBL] [Abstract][Full Text] [Related]
13. Orthopedia homeobox is preferentially expressed in typical carcinoids of the lung.
Hanley KZ; Dureau ZJ; Cohen C; Shin DM; Owonikoko TK; Sica GL
Cancer Cytopathol; 2018 Apr; 126(4):236-242. PubMed ID: 29316326
[TBL] [Abstract][Full Text] [Related]
14. Limited additive value of the Ki-67 proliferative index on patient survival in World Health Organization-classified pulmonary carcinoids.
Swarts DR; Rudelius M; Claessen SM; Cleutjens JP; Seidl S; Volante M; Ramaekers FC; Speel EJ
Histopathology; 2017 Feb; 70(3):412-422. PubMed ID: 27701763
[TBL] [Abstract][Full Text] [Related]
15. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
[TBL] [Abstract][Full Text] [Related]
16. Ascl1 and OTP tumour expressions are associated with disease-free survival in lung atypical carcinoids.
Centonze G; Maisonneuve P; Simbolo M; Lagano V; Grillo F; Prinzi N; Pusceddu S; Missiato L; Colantuono M; Sabella G; Bercich L; Mangogna A; Rolli L; Grisanti S; Benvenuti MR; Pastorino U; Roz L; Scarpa A; Berruti A; Capella C; Milione M
Histopathology; 2023 May; 82(6):870-884. PubMed ID: 36720841
[TBL] [Abstract][Full Text] [Related]
17. Proliferation Marker (Ki67) in Sub-Categorization of Neuroendocrine Tumours of the Lung.
Garg R; Bal A; DAS A; Singh N; Singh H
Turk Patoloji Derg; 2019; 35(1):15-21. PubMed ID: 30070306
[TBL] [Abstract][Full Text] [Related]
18. High-grade neuroendocrine carcinomas of the lung highly express enhancer of zeste homolog 2, but carcinoids do not.
Findeis-Hosey JJ; Huang J; Li F; Yang Q; McMahon LA; Xu H
Hum Pathol; 2011 Jun; 42(6):867-72. PubMed ID: 21292308
[TBL] [Abstract][Full Text] [Related]
19. Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of
Bongiovanni A; Recine F; Riva N; Foca F; Liverani C; Mercatali L; Nicolini S; Pieri F; Amadori D; Ibrahim T
Clin Lung Cancer; 2017 Jul; 18(4):415-420. PubMed ID: 27956089
[TBL] [Abstract][Full Text] [Related]
20. [Pulmonary carcinoid: analysis of a single institutional experience and prognostic factors].
Correia Sda S; Pinto C; Bernardo J
Acta Med Port; 2014; 27(6):749-54. PubMed ID: 25641291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
